1-20 of 131
Carlos L. Arteaga
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT271: Neoadjuvant targeted therapy in stage I-III HER2-mutant lobular breast cancer

Laura C. Kennedy, Nisha Unni, Ariella B. Hanker, Carlos L. Arteaga
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT271.
https://doi.org/10.1158/1538-7445.AM2024-CT271
Published: 05 April 2024
View article titled, Abstract CT271: Neoadjuvant targeted therapy in stage I-III HER2-mutant lobular breast cancer
Journal Articles

Abstract 7592: Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)

Rosario Chica-Parrado, Gun Min Kim, Yasuaki Uemoto, Dan Ye, Fabiana Napolitano, Chang-Ching Lin, Emmanuel Bikorimana, Kyung-min Lee, Saurabh Mendiratta, Ariella B. Hanker, Carlos L. Arteaga
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7592.
https://doi.org/10.1158/1538-7445.AM2024-7592
Published: 22 March 2024
View article titled, Abstract 7592: Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)
Journal Articles

Abstract 2493: Prospective evaluation of predictive biomarkers for Palbociclib (P) and endocrine therapy (ET) benefit in hormone receptor (HR)-positive [+]/human epidermal growth factor receptor 2 (HER2)-negative [-] advanced breast cancer (ABC) patients (pts) from PARSIFAL clinical trial: The transFAL sub-study

Joan Albanell, Angelo Gámez Pozo, Carlos L. Arteaga, Meritxell Bellet, Federico Rojo, Abel González, Beatriz Bellosillo, Violeta Serra, Petra Gener, José Antonio Guerrero, Laura López-Montero, Mario Mancino, Jose Rodríguez-Morató, Leonardo Mina, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2493.
https://doi.org/10.1158/1538-7445.AM2024-2493
Published: 22 March 2024
View article titled, Abstract 2493: Prospective evaluation of predictive biomarkers for Palbociclib (P) and endocrine therapy (ET) benefit in hormone receptor (HR)-positive [+]/human epidermal growth factor receptor 2 (HER2)-negative [-] advanced breast cancer (ABC) patients (pts) from PARSIFAL clinical trial: The transFAL sub-study
Journal Articles

Abstract 3308: A selective FGFR1/2 degrader overcomes endocrine resistance in ER+/FGFR1-amplified andFGFR1/2-mutant breast cancer

Yasuaki Uemoto, Chang-Ching Lin, Bingnan Wang, Dan Ye, Emmanuel Bikorimana, Alberto Servetto, Luigi Formisano, Fabiana Napolitano, Rosario Chica Parrado, Saurabh Mendiratta, Chuo Chen, Ariella B. Hanker, Carlos L. Arteaga
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3308.
https://doi.org/10.1158/1538-7445.AM2024-3308
Published: 22 March 2024
View article titled, Abstract 3308: A selective FGFR1/2 degrader overcomes endocrine resistance in ER+/<em>FGFR1-amplified</em> and<em>FGFR1/2</em>-mutant breast cancer
Journal Articles

AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer

Mauricio Marquez-Palencia, Luis Reza Herrera, Pravat Kumar Parida, Suvranil Ghosh, Kangsan Kim, Nikitha M. Das, Paula I. Gonzalez-Ericsson, Melinda E. Sanders, Bret C. Mobley, Sebastian Diegeler, Todd A. Aguilera, Yan Peng, Cheryl M. Lewis, Carlos L. Arteaga, Ariella B. Hanker, Angelique W. Whitehurst, James B. Lorens, Rolf A. Brekken, Anthony J. Davis, Srinivas Malladi
Journal: Cancer Research
Cancer Res (2024) 84 (5): 675–687.
https://doi.org/10.1158/0008-5472.CAN-23-1459
Published: 04 March 2024
View article titled, AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2<sup>+</sup> Breast Cancer
Open the PDF for AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2<sup>+</sup> Breast Cancer in another window
Includes: Supplementary data
Journal Articles

AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients

Carlos L. Arteaga, John L. Cleveland, Margaret Foti, Ruben A. Mesa, Louis M. Weiner, Cheryl L. Willman, David A. Tuveson
Journal: Cancer Research
Cancer Res (2023) 83 (21): 3504–3506.
https://doi.org/10.1158/0008-5472.CAN-23-2803
Published: 01 November 2023
View article titled, AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients
Open the PDF for AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients in another window
Journal Articles

Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer

Arnaldo Marín, Abdullah Al Mamun, Hima Patel, Hiroaki Akamatsu, Dan Ye, Dhivya R. Sudhan, Lisa Eli, Katherine Marcelain, Benjamin P. Brown, Jens Meiler, Carlos L. Arteaga, Ariella B. Hanker
Journal: Cancer Research
Cancer Res (2023) 83 (18): 3145–3158.
https://doi.org/10.1158/0008-5472.CAN-22-3617
Published: 15 September 2023
View article titled, Acquired Secondary <em>HER2</em> Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
Open the PDF for Acquired Secondary <em>HER2</em> Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 3934: PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER+/Rb-deficient breast cancer

Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Yanfeng Zhang, Andrew Lemoff, Yisheng V. Fang, He Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-min Lee, Xuemei Luo, Joseph J. Otto, Hiroaki Akamatsu, David W. Cescon, Lin Xu, Yang Xie, Joshua T. Mendell, Ariella B. Hanker, Carlos L. Arteaga
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3934.
https://doi.org/10.1158/1538-7445.AM2023-3934
Published: 04 April 2023
View article titled, Abstract 3934: PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER+/Rb-deficient breast cancer
Journal Articles

Abstract 3445: Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy

Fabiana Napolitano, Dhivya R. Sudhan, Yunguan Wang, Paula I. González-Ericsson, Luigi Formisano, Kyung-Min Lee, Chang-Ching Lin, María Rosario Chica-Parrado, Hongli Ma, Nathaniel Evans, Alberto Servetto, Saurabh Mendiratta, Spencer Barnes, Yisheng V. Fang, Justin M. Balko, Gordon B. Mills, Marilyne Labrie, Ariella B. Hanker, Carlos L. Arteaga
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3445.
https://doi.org/10.1158/1538-7445.AM2023-3445
Published: 04 April 2023
View article titled, Abstract 3445: Immune cells infiltration and activation are higher in breast cancers resistant to antiestrogen therapy
Journal Articles

Abstract 5483: Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)

Maria del Rosario Chica-Parrado, Gun Min Kin, Chang-Ching Lin, Kyung-min Lee, Fabiana Napolitano, Dan Ye, Emmanuel Bikorimana, Saurabh Mendirata, Ariella Hanker, Carlos L. Arteaga
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5483.
https://doi.org/10.1158/1538-7445.AM2023-5483
Published: 04 April 2023
View article titled, Abstract 5483: Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)
Journal Articles

Abstract 2699: Glucocorticoid receptor biology in lobular breast cancer

Candace Frerich, Ishrat Durdana, Ariella Hanker, Carlos L. Arteaga, Lynda Bennett, Suzanne Conzen
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2699.
https://doi.org/10.1158/1538-7445.AM2022-2699
Published: 15 June 2022
View article titled, Abstract 2699: Glucocorticoid receptor biology in lobular breast cancer
Journal Articles

Abstract CT160: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L

Vivek Subbiah, Fengmin Fengmin, Ragini Kudchadkar, Ryan J. Sullivan, Edith P. Mitchell, John J. Wright, Helen X. Chen, Robert J. Gray, Xin Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Tilak K. Sundaresan, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT160.
https://doi.org/10.1158/1538-7445.AM2022-CT160
Published: 15 June 2022
View article titled, Abstract CT160: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L
Journal Articles

Abstract 4197: Treatment with chemotherapy, CD40 agonist, and Flt3 ligand triplet combination enhances antigen presentation and leads to cures in triple negative breast cancer

Vijay Ramani, Shruthi Nooka, Yu-An Zhang, Serena Gibbs, Hai-Cheng Huang, Melanie Hullings, Suzanne Conzen, Carlos L. Arteaga, Isaac Chan, Sangeetha M. Reddy
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4197.
https://doi.org/10.1158/1538-7445.AM2022-4197
Published: 15 June 2022
View article titled, Abstract 4197: Treatment with chemotherapy, CD40 agonist, and Flt3 ligand triplet combination enhances antigen presentation and leads to cures in triple negative breast cancer
Journal Articles

Abstract PD2-01: A platform of CDK4/6 inhibitor-resistant patient-derived breast cancer organoids illuminates mechanisms of resistance and therapeutic vulnerabilities

Ariella B. Hanker, Sumanta Chatterjee, Yunguan Wang, Dan Ye, Dhivya R. Sudhan, Brian M. Larsen, Lauren C. Smith, Yilin Zhang, Vishal Kandagatla, Kuntal Majmudar, Ezequiel Renzulli, Saurabh Mendiratta, Kimberly Blackwell, Alana L. Welm, Sunati Sahoo, Nisha Unni, Cheryl M. Lewis, Tao Wang, Ameen A. Salahudeen, Carlos L. Arteaga
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD2-01.
https://doi.org/10.1158/1538-7445.SABCS21-PD2-01
Published: 15 February 2022
View article titled, Abstract PD2-01: A platform of CDK4/6 inhibitor-resistant patient-derived breast cancer organoids illuminates mechanisms of resistance and therapeutic vulnerabilities
Journal Articles

Abstract P5-17-09: A genome-wide CRISPR screen identifies PRMT5 as a novel therapeutic target in ER+/RB1-deficient breast cancer

Chang-Ching Lin, Tsung-Cheng Chang, Alberto Servetto, Kyung-min Lee, He Zhang, Yunguan Wang, Dan Ye, Sumanta Chatterjee, Dhivya R Sudhan, Hiroaki Akamatsu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-17-09.
https://doi.org/10.1158/1538-7445.SABCS21-P5-17-09
Published: 15 February 2022
View article titled, Abstract P5-17-09: A genome-wide CRISPR screen identifies PRMT5 as a novel therapeutic target in ER+/<em>RB1</em>-deficient breast cancer
Journal Articles

Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies

Aleix Prat, Nadia Solovieff, Faye Su, Aditya Bardia, Patrick Neven, Gabriel N. Hortobagyi, Debu Tripathy, Stephen Chia, Dennis Slamon, Yen-Shen Lu, Tetiana Taran, Agnes Lteif, Carlos L. Arteaga, Fabrice André
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD2-05.
https://doi.org/10.1158/1538-7445.SABCS21-PD2-05
Published: 15 February 2022
View article titled, Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies
Journal Articles

Abstract GS3-09: Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer

Dhivya R. Sudhan, Sumanta Chatterjee, Jiwoong Kim, Yunguan Wang, Vishal Kandagatla, Dan Ye, Chang-Ching Lin, Jorge Gomez Tejeda Zanudo, Esha Jain, Arnaldo Marin, Alberto Servetto, Kyung-min Lee, Juan Manuel Povedano, David McFadden, Alex Barrett, Nikhil Wagle, Ariella B. Hanker, Carlos L. Arteaga
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS3-09.
https://doi.org/10.1158/1538-7445.SABCS21-GS3-09
Published: 15 February 2022
View article titled, Abstract GS3-09: Loss of <em>ASXL1</em> tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer
Journal Articles

Abstract P4-01-02: A spectrum of secondary mutations in HER2 augment breast cancer cell growth and reduce neratinib sensitivity in HER2-mutant breast cancer

Arnaldo Andres Marin, Abdullah Al Mamun, Hiroaki Akamatsu, Dan Ye, Dhivya Sudhan, Benjamin Brown, Monica Red Brewer, Lisa Eli, Jens Meiler, Carlos L Arteaga, Ariella B Hanker
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-01-02.
https://doi.org/10.1158/1538-7445.SABCS21-P4-01-02
Published: 15 February 2022
View article titled, Abstract P4-01-02: A spectrum of secondary mutations in <em>HER2</em> augment breast cancer cell growth and reduce neratinib sensitivity in <em>HER2</em>-mutant breast cancer
Journal Articles

Abstract P4-10-02: Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy

Karen L Smith, Fengmin Zhao, Ingrid A Mayer, Amye J Tevaarwerk, Sofia F Garcia, Carlos L Arteaga, William F Symmans, Ben H Park, Brian L Burnette, Della F Makower, Margaret Block, Kimberly A Morley, Chirag R Jani, Craig Mescher, Shabana J Dewani, Ursa Brown-Glaberman, Lisa E Flaum, Erica L Mayer, William M Sikov, Eve T Rodler, Angela M DeMichele, Joseph A Sparano, Antonio C Wolff, Kathy D Miller, Lynne I Wagner
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P4-10-02.
https://doi.org/10.1158/1538-7445.SABCS21-P4-10-02
Published: 15 February 2022
View article titled, Abstract P4-10-02: Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy
Journal Articles

Abstract P5-04-02: Modulation of glucocorticoid receptor activity in invasive lobular carcinoma progression

Candace Frerich, Ishrat Durdana, Sumanta Chatterjee, Ariella Hanker, Lynda Bennett, Carlos L. Arteaga, Suzanne D. Conzen
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-04-02.
https://doi.org/10.1158/1538-7445.SABCS21-P5-04-02
Published: 15 February 2022
View article titled, Abstract P5-04-02: Modulation of glucocorticoid receptor activity in invasive lobular carcinoma progression